BioSpace News Archive

Masimo Corporation issued a letter to stockholders in connection with the Company’s 2024 Annual Meeting of Stockholders.

ChromaDex Corp., the global authority on nicotinamide adenine dinucleotide research with a focus on healthy aging, announced its inclusion in the Russell 2000® Index as part of the annual reconstitution of the Russell stock indexes.

TRACON Pharmaceuticals (NASDAQ: TCON) today announced the objective response rate (ORR) by blinded independent central review (BICR) in the fully enrolled ENVASARC pivotal trial in the 82 evaluable patients is 5% (four responders), which is lower than the primary endpoint of the study of 11% ORR by BICR needed to support a biologics license application (BLA).

The Leukemia & Lymphoma Society named five new members to its board of directors effective July 1, 2024, whose diverse experience and interests will be instrumental in helping the organization carry out its mission to cure blood cancer and improve the quality of life of all patients and their families.

Enzolytics, Inc. (OTC PINK:ENZC) (“enzolytics.com”) (the “Company”) announced today that the Company is entering into a worldwide exclusive licensing agreement for US Patent # 8067531-B2, “Inactivated pepsin fragments for modulating immune system activity against human malignant tumor cells,” applying Immunotherapy Treatment to the global fight against cancer.

Spur Therapeutics, formerly Freeline Therapeutics, today announced new data from its GBA1 Parkinson’s disease research program demonstrating that its rationally engineered GCase85 enzyme reduces the accumulation of α-Synuclein, a protein that plays a significant role in the development and progression of Parkinson’s disease, more effectively than wildtype glucocerebrosidase (GCase) in in vitro studies.

InspireMD, Inc., developer of the CGuard™ Embolic Prevention Stent System for the prevention of stroke, announced the completion of the full exercise of 12.9 million Series H warrants.

Delphinus Medical Technologies, a pioneering medical imaging company that developed the SoftVue™ Breast Ultrasound Tomography, announced the publication of a study comparing mammography in conjunction with SoftVue UST vs mammography alone in women with dense breasts.

Senti Biosciences, Inc., a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, announced that the California Institute for Regenerative Medicines has awarded an $8 million grant to Senti Bio.

Ovid Therapeutics Inc. and Graviton Bioscience Corporation today announced the results from their Phase 1 healthy volunteer study evaluating the safety, tolerability, and pharmacokinetic (PK) profile of multiple ascending doses of OV888/GV101 capsule.